A Phase II Trial of Avutometinib in Combination With Defactinib in Metastatic Diffuse Gastric Cancer

Bookmark
Investigational drug late phase More information Active drug More information Moderate burden on patient More information

Trial Details

Sponsor: Ryan H. Moy, MD, PhD (other)

Phase: 2

Start date: Oct. 28, 2024

Planned enrollment: 27

Trial ID: NCT06487221
Copy trial ID
More trial details at ClinicalTrials.gov More info

chevron Show Summary from Sponsor

Investigational Drug AI Analysis

chevron Show for: Defactinib (PF-04554878, VS-6063)

chevron Show for: Avutometinib (RO-5126766, CKI-27, CH-5126766, R-7304, RG-7304, VS-6766)

TrialFetch AI Analysis

Goal: Evaluate whether avutometinib plus defactinib controls previously treated metastatic or unresectable diffuse-type gastric cancer, with a primary focus on the proportion of patients alive without progression at 6 months. Safety and other efficacy measures will also be assessed.

Patients: Adults with unresectable or metastatic gastric or gastroesophageal junction carcinoma that is diffuse-type, poorly cohesive, signet ring cell, or mixed type; patients with pathogenic CDH1 or RHOA mutations are eligible regardless of histology. Patients must have received at least one platinum- and fluoropyrimidine-containing regimen for advanced disease, have an ECOG performance status of 0–1, adequate organ function, radiographically evaluable disease, and tumor accessible for a fresh biopsy or malignant ascites sampling.

Design: Single-arm, nonrandomized phase II treatment study; all participants receive the same combination. There is no comparator arm.

Treatments: Avutometinib 3.2 mg orally twice weekly plus defactinib 200 mg orally twice daily, both given for three weeks followed by one week off. Avutometinib inhibits RAF–MEK signaling, while defactinib inhibits focal adhesion kinase (FAK), a potential adaptive survival pathway. In previously treated low-grade serous ovarian cancer, the combination produced a 31% response rate overall in a phase II study, including 44% in KRAS-mutated disease; those results do not establish efficacy in gastric cancer.

Outcomes: The primary endpoint is the 6-month progression-free survival rate. Secondary endpoints include RECIST 1.1 objective response rate, median progression-free survival, overall survival, disease control rate, and duration of response. The listed disease-control definition includes progressive disease, which appears inconsistent with the conventional definition and warrants clarification.

Burden on patient: Moderate anticipated burden. Treatment is oral but requires dosing on multiple days each week in repeating four-week cycles, follow-up visits and imaging for response assessment, and safety monitoring. Eligibility requires fresh tumor sampling or paracentesis of malignant ascites, adding a procedure; cardiac, laboratory, and ECG screening may also be needed. Visit and imaging frequency are not specified, and intensive pharmacokinetic blood sampling is not described.

Last updated: Sep 2026

Eligibility More information

chevron Show Criteria

Sites (1)

Sort by distance to:
Clear

Columbia University Irving Medical Center

New York, New York, 10032, United States

[email protected] / 212-342-5162

Status: Recruiting

Back to trials list